Quantum Biopharma (QNTM) Change in Receivables (2019 - 2026)
Quantum Biopharma's (QNTM) quarterly Change in Receivables came in at $22529.0 in Q1 2026, down 77.34% year-on-year from $99417.0 in Q1 2025, and up 122.6% quarter-over-quarter from -$99701.0 in Q4 2025.
Quantum Biopharma (QNTM) Change in Receivables (2019 - 2026) Analysis & Trends
Quantum Biopharma has disclosed Change in Receivables across 8 years of filings, most recently posting $22529.0 for Q1 2026.
- Change in Receivables for Q1 2026 came in at $22529.0, down 77.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$248229.0 (down 101.13% YoY), and the FY2025 annual result was $231053.0, down 38.33% from the prior year.
- Change in Receivables came in at $22529.0 for Q1 2026 at Quantum Biopharma, up from -$99701.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $951503.0 in Q2 2022 to a low of -$270474.0 in Q4 2024.
- The 5-year median for Change in Receivables is $86868.0 (2024), against an average of $128906.5.
- Peak annual rise in Change in Receivables reached 222.74% in 2024, while the deepest fall reached 1758.42% in 2024.
- Quantum Biopharma's Change in Receivables stood at -$49813.0 in 2022, then jumped by 70.78% to -$14554.0 in 2023, then plunged by 1758.42% to -$270474.0 in 2024, then jumped by 63.14% to -$99701.0 in 2025, then soared by 122.6% to $22529.0 in 2026.
- The last three Change in Receivables figures came in at $22529.0 (Q1 2026), -$99701.0 (Q4 2025), and $78300.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | -1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22,529.00 |
| Mar 31, 2026 | 22,529.00 |
| Dec 31, 2025 | -99,701.00 |
| Dec 31, 2025 | -99,701.00 |
| Sep 30, 2025 | 78,300.00 |
| Sep 30, 2025 | 78,300.00 |
| Jun 30, 2025 | 193,198.00 |
| Jun 30, 2025 | 193,198.00 |
| Mar 31, 2025 | 99,417.00 |
| Mar 31, 2025 | 99,417.00 |
| Dec 31, 2024 | -270,474.00 |
| Dec 31, 2024 | -270,474.00 |
| Sep 30, 2024 | 104,204.00 |
| Sep 30, 2024 | 104,204.00 |
| Jun 30, 2024 | 86,868.00 |
| Jun 30, 2024 | 86,868.00 |
| Mar 31, 2024 | 62,196.00 |
| Mar 31, 2024 | 62,196.00 |
| Dec 31, 2023 | -14,554.00 |
| Dec 31, 2023 | -14,554.00 |